Bio-Techne

Bio-Techne is listed on the NASDAQ under the ticker symbol TECH. Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...", a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch. Interviewing investor Edward B. White for the New York Times, Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist." Beginning in 2013, the company's chief executive officer was Charles (Chuck) Kummeth, who had previously been employed by 3M and Thermo Fisher Scientific. In an article by the Star Tribune, Joe Carlson wrote "Analysts like how Bio-Techne is growing, combining well-considered acquisition targets with the company's long-running reputation for producing top-quality raw proteins and antibodies for use in research." Acquisitions

• 2013: Bionostics for $104 million
• 2014: Novus Biologicals for $60 million, ProteinSimple for $300 million, PrimeGene, CyVek
• 2015: Cliniqa Corporation
• 2016: Zephyrus Biosciences Advanced Cell Diagnostics for $325 million
• 2017: Trevigen
• 2018: Atlanta Biologicals, Quad Technologies, Exosome Diagnostics for up to $575 million